InflaRx

IFRX

Jena, Germany· Est. 2007

inflarx.de

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

IFRX · Stock Price

USD 2.65+1.04 (+64.60%)

Market Cap: $187.2M

Historical price data

Market Cap: $187.2MPipeline: 15 drugs (2 Phase 3)Founded: 2007Employees: 50-100HQ: Jena, Germany

Sector Ranking#157 in Biologics / Biosimilars

Overview

InflaRx is a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics targeting the C5a/C5aR pathway of the complement system. Its most significant achievement is the FDA Emergency Use Authorization for vilobelimab (GOHIBIC) in critically ill COVID-19 patients. The company's strategy involves leveraging its selective C5a inhibition platform to address both acute, life-threatening conditions like ARDS and chronic inflammatory diseases such as pyoderma gangrenosum, though recent Phase 3 setbacks in the latter have refocused efforts on acute care and other indications.

Inflammatory DiseasesCritical CareImmunology

Technology Platform

Proprietary platform for developing selective inhibitors of the complement activation factor C5a and its receptor C5aR, designed to control harmful inflammation while preserving protective immune functions.

Pipeline

15 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
vilobelimab + Placebo	Pyoderma Gangrenosum	Phase 3
IFX-1 + BSC + BSC + IFX-1 + SOC + Placebo + SOC	Severe COVID-19 Pneumonia	Phase 2/3
Cohort A: vilobelimab + Cohort A: placebo + Cohort B: paridi...	Acute Respiratory Distress Syndrome (ARDS)	Phase 2
IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucoc...	Granulomatosis With Polyangiitis (GPA)	Phase 2
Cohort C: bevacizumab + Cohort C: placebo	Acute Respiratory Distress Syndrome (ARDS)	Phase 2

Funding History

Total raised:$100M

IPO$60MUndisclosedNov 9, 2017

Series B$30MMPM CapitalJun 15, 2015

Series A$10MMPM CapitalJun 15, 2013

Opportunities

The significant unmet need in non-COVID ARDS, a condition with no approved pharmacologic therapies, presents a multi-billion dollar market opportunity for vilobelimab.

Success here could also validate the selective C5a inhibition approach for other acute inflammatory conditions, potentially making InflaRx an attractive strategic acquisition target.

Risk Factors

The company faces imminent financial risk with a low cash runway and depressed valuation, compounded by high clinical risk following a Phase 3 failure.

Its future is binary, dependent on the success of vilobelimab in non-COVID ARDS, a trial area with a history of failures.

Competitive Landscape

InflaRx competes in the complement space against giants like AstraZeneca (broad C5 inhibitors) and Amgen (oral C5aR inhibitor avacopan). Its differentiation lies in selective C5a (ligand) inhibition, but it must prove clinical superiority or a unique safety advantage in specific indications to capture market share.